TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemo

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.27) per share which missed the

Planned merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in RA

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's

Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday'

Chemomab Therapeutics (NASDAQ:CMMB) ("Chemomab") and Scipher Medicine Corporation ("Scip

Chemomab and Scipher announced a merger agreement to advance nebokitug into a Phase 2 precision medi

Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's

Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.24) per share which beat the an

—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disea

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.24) per share which beat the an

2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance alon

TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemo

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ: CMMB - Get Free Report) saw a significant growth i

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company develo

— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifyin

TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemo

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.28) per share which beat the an

—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment

— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in K

Chemomab announced three presentations "of distinction" at AASLD The Liver Meeting® 2025 featuring c

PARR, CMMB and GES made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 23, 2025.

MQ, GES, TRV, CMMB and PARR have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 23, 2025.

Oppenheimer analyst Jeff Jones maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform an

TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemo

Juba, South Sudan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) is launch

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.09) per share which missed the

— Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Execu

SPRING Trial Data Presented at BSG Live'25 Confirms the Clinical Potential of Nebokitug as a First-i

—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Pr

—New Patents Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Scleros

—New Patent s Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclero

Oppenheimer analyst Jeff Jones maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform an

SPRING Trial Data Presented at Digestive Disease Week® 2025 Shows that Nebokitug at 15 and 48 Weeks 

New Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated

Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in li

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Feature

Maxim Group analyst Michael Okunewitch maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Buy a

CMMB: 41% | Chemomab Therapeutics shares are trading higher after the company announced the completi

Oppenheimer analyst Jeff Jones reiterates Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform a

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.20) per share which missed the

Chemomab had previously announced on November 6, 2023, that it was notified by Nasdaq that it was no

Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosi